A Phase 2a, Open-label, Dose Finding Study to Determine the Safety and Tolerability of SOTATERCEPT (ACE-011) in Adults With Beta-Thalassemia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Sotatercept (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 23 Oct 2017 Planned End Date changed from 1 Feb 2020 to 31 Dec 2024.
- 19 Jan 2017 Planned End Date changed from 1 Nov 2019 to 1 Feb 2020.
- 01 Apr 2016 Trial design has been changed from single group assignment to parallel assignment.